Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 299.55 DKK 0.18%
Market Cap: 1.3T DKK

Novo Nordisk A/S
Current Portion of Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Novo Nordisk A/S
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Novo Nordisk A/S
CSE:NOVO B
Current Portion of Long-Term Debt
kr12B
CAGR 3-Years
87%
CAGR 5-Years
52%
CAGR 10-Years
N/A
H Lundbeck A/S
CSE:HLUN A
Current Portion of Long-Term Debt
kr82m
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ALK-Abello A/S
CSE:ALK B
Current Portion of Long-Term Debt
kr65m
CAGR 3-Years
-32%
CAGR 5-Years
6%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Current Portion of Long-Term Debt
kr1.5m
CAGR 3-Years
80%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Novo Nordisk A/S
Glance View

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
HIDDEN
Show

See Also

What is Novo Nordisk A/S's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
12B DKK

Based on the financial report for Sep 30, 2025, Novo Nordisk A/S's Current Portion of Long-Term Debt amounts to 12B DKK.

What is Novo Nordisk A/S's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
52%

Over the last year, the Current Portion of Long-Term Debt growth was 118%. The average annual Current Portion of Long-Term Debt growth rates for Novo Nordisk A/S have been 87% over the past three years , 52% over the past five years .

Back to Top